Well, it looks like Amarin (NAS: AMRN) investors will have to wait a little bit longer -- again -- to discover whether the FDA grants the company's hypertriglyceridemia drug Vascepa New Chemical Entity (NCE) status. The FDA updated its database of approved drugs today, and many believed that Vascepa would either be given or denied the NCE designation. This issue has kept Amarin in neutral during the past few months, and negotiations with possible partners or acquirers, such as AstraZeneca (NYS: AZN) and Teva (NYS: TEVA) , have stalled.
In this video, health-care analysts David Williamson and Max Macaluso discuss this ongoing delay, and how it impacts Amarin's plans going forward.
The biotech space can make or break investors overnight and, while Amarin might not disappear into thin, the success of its new triglyceride-lowering drug is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.
The article No News Equals Bad News for Amarin Investors originally appeared on Fool.com.
David Williamson owns shares of Amarin plc (ADR). Max Macaluso, Ph.D. has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.